Table 3.
Correlation analysis between survivor subgroups and oncogenic mutation; n = 39. Fisher’s exact test was used to test for significance (p-value < 0.05 indicates significance).
| Mutational Status | OS | OS | DFS | DFS | ||
|---|---|---|---|---|---|---|
| <4 Years | ≥4 Years | p-Value | <2 Years | ≥2 Years | p-Value | |
| n = 31 | n = 8 | n = 32 | n = 7 | |||
| KRAS NGS | ||||||
| G12D | 13 | 1 | 0.015 | 14 | 0 | 0.005 |
| G12V/R/C and WT | 18 | 4 | 18 | 4 | ||
| Q61H/D57N | 0 | 3 | 0 | 3 | ||
| TP53 NGS | ||||||
| NS + SS | 5 | 0 | 0.563 | 5 | 0 | 0.563 |
| WT + MS | 26 | 8 | 27 | 7 | ||
| SMAD4 NGS | ||||||
| Yes | 4 | 1 | 1.000 | 5 | 0 | 0.898 |
| No | 27 | 7 | - | - | ||
| Other 3rd driver mutation | ||||||
| Yes | 11 | 2 | 0.751 | 11 | 2 | 0.884 |
| No | 20 | 6 | 21 | 5 | ||
| p53 IHC | ||||||
| Aberrant | 15 | 5 | 1.000 | 16 | 4 | 1.000 |
| Normal | 12 | 3 | 12 | 3 | ||
| p16 IHC | ||||||
| Normal | 8 | 2 | 1.000 | 8 | 2 | 1.000 |
| Loss | 20 | 6 | 21 | 5 | ||
| Smad4 IHC | ||||||
| Normal | 8 | 3 | 0.672 | 7 | 4 | 0.163 |
| Loss | 21 | 5 | 23 | 3 | ||
DFS: disease-free survival; IHC: immunohistochemistry; NGS: next generation sequencing; NS: nonsense; MS: missense; OS: overall survival; SS: splice site; WT: wild type.